Altimmune (NYSE: ALT) — Perfil da empresa, notícias e dados financeiros
Altimmune is a biopharmaceutical company focused on treatments for respiratory diseases and immune-modulating therapies like vaccines.

Altimmune
Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.
Resumo
Operações
Produtos e/ou serviços de Altimmune
- HepTcell, a therapeutic vaccine candidate for the treatment of chronic hepatitis B.
- AdCOVID, a single-dose intranasal vaccine candidate for COVID-19.
- T-COVID, an intranasal immunomodulator treatment for early COVID-19.
- ALT-801, a novel GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH).
- NasoShield, an anthrax vaccine candidate administered through a single intranasal dose.
- NasoVAX, an intranasal influenza vaccine candidate designed to provide long-lasting protection.
equipe executiva do Altimmune
- Jerome Benedict DursoChairman, CEO & President
- M. Scot RobertsChief Scientific Officer
- Christophe Arbet-EngelsChief Medical Officer
- Gregory L. WeaverChief Financial Officer
- Richard MenziusoVP, Global Controller & Principal Accounting Officer
- Bertrand GeorgesChief Technology Officer
- Luis SanayVice President of Investor Relations
- Tony BlandinVice President of Quality & Compliance Management
- Robin E. AbramsChief Legal Officer & Corporate Secretary
- Raymond M. JordtChief Business Officer
Comunicados recentes
O que a Altimmune (ALT) comunicou ao mercado, do mais recente para o mais antigo.
Histórico de dividendos
Dividendos por ação pagos pela Altimmune, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2016 | — | $875.9200 | — | $875.9200 |
Principais indicadores financeiros
Resultados divulgados pela Altimmune, em USD.
- Cap. de mercado
- 274,4 mi
- Receita (TTM)
- 26 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 41 mil | -94,5 mi | -88,1 mi | |
| 20 mil | -103,2 mi | -95,1 mi | |
| 426 mil | -95,9 mi | -88,4 mi | |
| -68 mil | -87,7 mi | -84,7 mi |